IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
-14.72%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$9.59M
AUM Growth
+$9.59M
(-98%)
Cap. Flow
-$470M
Cap. Flow
% of AUM
-4,907.13%
Top 10 Holdings %
Top 10 Hldgs %
47.01%
Holding
85
New
15
Increased
1
Reduced
62
Closed
7
Top Buys
| 1 |
CNCE
Concert Pharmaceuticals, Inc.
CNCE
|
$620K |
| 2 |
Exelixis
EXEL
|
$350K |
| 3 |
Caribou Biosciences
CRBU
|
$255K |
| 4 |
Galapagos
GLPG
|
$123K |
| 5 |
Ironwood Pharmaceuticals
IRWD
|
$60K |
Top Sells
| 1 |
Dyne Therapeutics
DYN
|
$68.7M |
| 2 |
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
|
$61.1M |
| 3 |
Aurinia Pharmaceuticals
AUPH
|
$42.8M |
| 4 |
KalVista Pharmaceuticals
KALV
|
$38.7M |
| 5 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$20.4M |
Sector Composition
| 1 | Healthcare | 91.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CNCE
1
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $620K | 6.47% | +2,610 | New | +$620K |
|
|
2
Aurinia Pharmaceuticals
AUPH
$1.58B
| $574K | 5.98% | 5,758 -429,242 | -99% | -$42.8M |
|
|
3
Dyne Therapeutics
DYN
$1.92B
| $563K | 5.87% | 3,865 -472,135 | -99% | -$68.7M |
|
|
IMAB
4
I-MAB
IMAB
$340M
| $553K | 5.77% | 6,232 -11,768 | -65% | -$1.04M |
|
5
uniQure
QURE
$896M
| $447K | 4.66% | 8,318 -147,182 | -95% | -$7.9M |
|
|
6
KalVista Pharmaceuticals
KALV
$678M
| $383K | 4% | 3,760 -379,473 | -99% | -$38.7M |
|
7
Travere Therapeutics
TVTX
$1.56B
| $380K | 3.96% | 9,215 -370,785 | -98% | -$15.3M |
|
|
8
Exelixis
EXEL
$10.1B
| $350K | 3.65% | +7,290 | New | +$350K |
|
|
KDNY
9
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $340K | 3.55% | 5,947 -334,442 | -98% | -$19.1M |
|
10
Supernus Pharmaceuticals
SUPN
$2.53B
| $298K | 3.1% | 8,604 -288,896 | -97% | -$9.99M |
|
|
HZNP
11
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $287K | 2.99% | 22,915 -160,558 | -88% | -$2.01M |
|
12
Vera Therapeutics
VERA
$1.38B
| $281K | 2.93% | 3,825 -186,924 | -98% | -$13.7M |
|
13
Iovance Biotherapeutics
IOVA
$807M
| $273K | 2.85% | 3,011 -54,989 | -95% | -$4.99M |
|
|
14
Caribou Biosciences
CRBU
$174M
| $255K | 2.66% | +1,378 | New | +$255K |
|
15
Incyte
INCY
$16.5B
| $238K | 2.48% | 18,081 -219,919 | -92% | -$2.89M |
|
16
Neurocrine Biosciences
NBIX
$13.8B
| $236K | 2.46% | 23,008 -179,992 | -89% | -$1.85M |
|
17
Harmony Biosciences
HRMY
$2.12B
| $222K | 2.31% | 10,794 -194,680 | -95% | -$3.99M |
|
18
Fulcrum Therapeutics
FULC
$351M
| $194K | 2.02% | 949 -81,792 | -99% | -$16.7M |
|
19
Ultragenyx Pharmaceutical
RARE
$2.89B
| $161K | 1.68% | 9,610 -223,490 | -96% | -$3.75M |
|
20
Fate Therapeutics
FATE
$120M
| $158K | 1.65% | 3,917 -24,083 | -86% | -$971K |
|
21
Gilead Sciences
GILD
$140B
| $146K | 1.52% | 9,012 -79,772 | -90% | -$1.29M |
|
|
MRTX
22
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $136K | 1.42% | 9,131 -179,369 | -95% | -$2.67M |
|
23
Novavax
NVAX
$1.21B
| $133K | 1.38% | 6,814 -125,686 | -95% | -$2.44M |
|
|
24
Galapagos
GLPG
$2.07B
| $123K | 1.29% | +6,876 | New | +$123K |
|
|
CCXI
25
DELISTED
ChemoCentryx, Inc.
CCXI
| $121K | 1.26% | 3,000 -33,100 | -92% | -$1.34M |
|